R&D
Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
- By IPP Bureau
| March 20, 2026
Viva Biotech is turbocharging the hunt for next-generation therapeutics by optimizing its Proteina-Complexa model to design mini-binders targeting ActRIIA, a key receptor linked to muscle wasting and lean mass imbalance. The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology.
The collaboration showcases Viva Biotech’s innovative “Lab-in-the-Loop” workflow, which merges de novo computational design with high-throughput protein production and biophysical evaluation to craft ActRIIA binders.
“This integrated approach demonstrates how in silico predictions with real-world experimental validations can expedite drug discovery,” the company said, highlighting the combined power of NVIDIA BioNeMo and Viva Biotech’s AI-driven platform in optimizing drug candidates.
Viva Biotech’s AI techniques for sequence selection have also refined the Proteina-Complexa model itself.
“This iteration led to more efficient and targeted mini-binder designs. Guided by AI-driven insights, we successfully explored previously uncharted chemical space and significantly enhanced design specificity, achieving these advances at a fraction of the cost and time compared with conventional drug candidate nomination processes,” the company added.
